ALK-Abelló

Report Publication Announcement • Dec 17, 2019

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

2020 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF):

Silent period	8 January 2020
Annual report 2019	5 February 2020
Annual General Meeting to be held at ALK Bøge Allé 1 2970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in the agenda if received by the company on 28 January 2020 at the latest (may be e-mailed to [email protected])	11 March 2020 4.00 p.m.
Silent period	8 April 2020
Three-month interim report (Q1) 2020	6 May 2020
Silent period	15 July 2020
Six-month interim report (Q2) 2020	12 August 2020
Silent period	14 October 2020
Nine-month interim report (Q3) 2020	11 November 2020

ALK-Abelló A/S

**

For further information please contact:**

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, mobile +45 3050 2014

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

• FM_22_19UK_17122019